Recent Pfizer Press Releases

  • 3/22/16 8:30 am EDT

    By Pooling Knowledge and Resources From Academia, Government, and Industry Partners, the Consortium Will Evaluate Human Immune Responses with the Goal to Potentially Speed Vaccines and Immunotherapeutic Development

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer. “Over the last decade, we’more...
  • 3/18/16 11:00 am EDT

    Detailed Results from OCTAVE Induction 1 and 2 Presented During Oral Session at 11th Congress of ECCO

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program at the 11th Congress of ECCO. Results from OCTAVE Induction 1 and OCTAVE Induction 2, evaluating the efficacy and safety of oral tofacitinib 10 mg twice daily (BID) in inducing remission in adult patients with moderately to severely activemore...
  • 3/16/16 8:00 am EDT

    Seven Abstracts, Including Pivotal Phase 3 Data in Ulcerative Colitis, Accepted for Presentation

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that seven abstracts reporting on new research for tofacitinib in ulcerative colitis (UC) and Crohn’s disease will be presented at the 11th Congress of ECCO, which will be held March 16-19 in Amsterdam, The Netherlands. Among the abstracts are detailed results from two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program. Tofacitinib is being studiedmore...
  • 3/15/16 1:53 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) released today its 2015 integrated annual review, an in-depth look into the company’s financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships. In the review, our scientists, researchers and business leaders offer in-depth looks at their projects and how they are working to discover and develop potential new medicines and vaccines to improvemore...
  • 3/11/16 1:10 pm EST

    XALKORI is the first and only FDA-approved biomarker-driven therapy for ROS1-positive metastatic NSCLC

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for XALKORI® (crizotinib) to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In 2015, the FDA granted Breakthrough Therapy and Priority Review designations for this indication. XALKORI also is indicated for patients with metastatic NSCLC whose tumors aremore...
  • 3/9/16 8:00 am EST

    Cedric “The Entertainer” discusses diagnosis and awareness disparities among diverse population groups

    NEW YORK & ALEXANDRIA, Va.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) in collaboration with the American Diabetes Association today announced results of a joint multicultural survey, Community Health Perspectives, which found significant gaps in awareness, diagnosis and management of a serious diabetes-related complication known as painful diabetic peripheral neuropathy or diabetic nerve pain. The findings were particularly pronounced among African American and Hispanic American communitiesmore...
  • 3/9/16 6:45 am EST

    Accelerated Share Repurchase Assumed in Pfizer’s 2016 Financial Guidance Issued on February 2, 2016

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase $5 billion of Pfizer’s common stock. This agreement is part of Pfizer’s existing share repurchase authorization. Approximately 136 million of the shares to be repurchased under the transaction will be received by Pfizer on March 10, 2016. At settlement of the agreement, whichmore...
  • 3/3/16 7:15 am EST
    • Collaboration will focus on a Phase I/Ib clinical trial expected to begin in the second half of 2016
    DARMSTADT, Germany & NEW YORK & BOSTON--(BUSINESS WIRE)--Merck, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected tomore...
  • 3/3/16 7:00 am EST
    • Collaboration will focus on a Phase I/Ib clinical trial expected to begin in the second half of 2016
    DARMSTADT, Germany, NEW YORK& BOSTON--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ibmore...
  • 3/1/16 11:30 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Cowen and Company 36th Annual Healthcare Conference on Tuesday, March 8, 2016 at 10:40 a.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Cowen and Company 36th Annual Healthcare Conferencemore...